Abstract 1346: Panel-based tumor mutational burden (TMB) analysis of matched tumor and plasma specimens using Illumina’s TruSight Oncology 500 next-generation sequencing assay
Stephanie B. Hastings(Q2 Solutions (United States)), Patrick Hurban(Q2 Solutions (United States)), Traci Pawlowski(Illumina (United States)), Rajiv Raja(AstraZeneca (United States)), Philip Z. Brohawn(Hofstra University), Zhao Chen(Zhejiang University of Technology), Gunjan Hariani(Q2 Solutions (United States)), Tingting Jiang(Illumina (United States)), Victor Weigman(University of North Carolina at Chapel Hill)
Cited by 0
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors
|Genome biology|2007|1.3k
Changes in circulating microRNA levels associated with prostate cancer
|British Journal of Cancer|2012|717
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
|The Lancet Rheumatology|2019|478